tildrakizumab is a humanized IgG1 kappa monoclonal antibody that selectively targets the p19 subunit of interleukin IL-23, thereby inhibiting the IL-23/IL-17 axis, which is primarily implicated in the immunopathogenesis of psoriasis. Tildrakizumab is approved for the treatment of moderate-to-severe plaque-type psoriasis in adults based on the evidence of two randomized and controlled phase-III clinical trials (reSURFACE 1 and reSURFACE 2). Here, we report our real-life experience treating 53 psoriatic patients (19 female and 34 male) who were administered tildrakizumab every 12 weeks and received follow-ups over 52 weeks. descriptive and inferential statistical analyses were performed, in particular the psoriasis area and severity Index (PASI), dermatology life quality Index (DLQI) and, if applicable, the Nail Psoriasis Severity Index (NAPSI) and Palmoplantar psoriasis physician global assessment (PPPGA). these were assessed at baseline and after different timepoints (weeks) during the follow-up period. we described and evaluated demographical and epidemiological characteristics in our cohort group, focusing on comorbidities. In this group, 35.9% of patients were female and 64.1% were male, with 47.1% being smokers and with a mean age of 51.2 years. a total of 37.7% of these patients was affected by scalp psoriasis; regarding comorbidities, hypertension was the most frequent (32.5%), followed by psoriatic arthritis (PsA) (18.60%) and diabetes (13.9%). at week 52, 93%, 90.2% and 77% of patients achieved a PASI reduction >= 75% (PASI 75), PASI 90 and PASI 100, respectively. In addition, NAPSI, PPPGA and DLQI scores were significantly reduced by week 52. In our cohort of complex psoriasis patients, disease remission began at the end of the fourth week of treatment and remained constant from week 16 to week 52.

Campione, E., Lambiase, S., Gaeta Shumak, R., Galluzzo, M., Lanna, C., Costanza, G., et al. (2023). A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients. PHARMACEUTICALS, 16(4) [10.3390/ph16040526].

A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients

Campione E.;Lambiase S.;Gaeta Shumak R.;Galluzzo M.;Lanna C.;Costanza G.
Data Curation
;
Borselli C.;Artosi F.;Cosio T.;Tofani L.;Dattola A.;Di Daniele F.;Bianchi L.
2023-01-01

Abstract

tildrakizumab is a humanized IgG1 kappa monoclonal antibody that selectively targets the p19 subunit of interleukin IL-23, thereby inhibiting the IL-23/IL-17 axis, which is primarily implicated in the immunopathogenesis of psoriasis. Tildrakizumab is approved for the treatment of moderate-to-severe plaque-type psoriasis in adults based on the evidence of two randomized and controlled phase-III clinical trials (reSURFACE 1 and reSURFACE 2). Here, we report our real-life experience treating 53 psoriatic patients (19 female and 34 male) who were administered tildrakizumab every 12 weeks and received follow-ups over 52 weeks. descriptive and inferential statistical analyses were performed, in particular the psoriasis area and severity Index (PASI), dermatology life quality Index (DLQI) and, if applicable, the Nail Psoriasis Severity Index (NAPSI) and Palmoplantar psoriasis physician global assessment (PPPGA). these were assessed at baseline and after different timepoints (weeks) during the follow-up period. we described and evaluated demographical and epidemiological characteristics in our cohort group, focusing on comorbidities. In this group, 35.9% of patients were female and 64.1% were male, with 47.1% being smokers and with a mean age of 51.2 years. a total of 37.7% of these patients was affected by scalp psoriasis; regarding comorbidities, hypertension was the most frequent (32.5%), followed by psoriatic arthritis (PsA) (18.60%) and diabetes (13.9%). at week 52, 93%, 90.2% and 77% of patients achieved a PASI reduction >= 75% (PASI 75), PASI 90 and PASI 100, respectively. In addition, NAPSI, PPPGA and DLQI scores were significantly reduced by week 52. In our cohort of complex psoriasis patients, disease remission began at the end of the fourth week of treatment and remained constant from week 16 to week 52.
2023
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/25
English
DLQI ; IL-17; NAPSI; PASI; PPPGA; comorbidities; psoriasis; tildrakizumab;
Campione, E., Lambiase, S., Gaeta Shumak, R., Galluzzo, M., Lanna, C., Costanza, G., et al. (2023). A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients. PHARMACEUTICALS, 16(4) [10.3390/ph16040526].
Campione, E; Lambiase, S; Gaeta Shumak, R; Galluzzo, M; Lanna, C; Costanza, G; Borselli, C; Artosi, F; Cosio, T; Tofani, L; Dattola, A; Di Daniele, F;...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
pharmaceuticals-16-00526.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 3.07 MB
Formato Adobe PDF
3.07 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/348183
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact